Table 5.
Clinical status1 | n | ADG1 | ADG2 | ADG-overall | ADG-PRE | ADG-POST |
---|---|---|---|---|---|---|
Healthy | 71 | 0.53a (0.07) | 0.17 (0.04) | 0.32 (0.03) | 0.16a (0.10) | 0.26a (0.04) |
sBRD2 | 14 | 0.45ab (0.14) | 0.09 (0.09) | 0.23 (0.07) | — | — |
BRD-no-con3 | 30 | 0.57a (0.10) | 0.22 (0.07) | 0.37 (0.05) | −0.26b (0.15) | 0.48b (0.06) |
BRD-con4 | 38 | 0.11b (0.10) | 0.30 (0.06) | 0.26 (0.05) | −0.44b (0.13) | 0.44b (0.06) |
1A matched healthy control calf corresponding to each individual BRD case was selected retrospectively from the nearest pen to compare ADG prior to and after treatment at the same times. ADGs calculated with individual body weights from day 0 to 28 (ADG1), day 28 to 65 (ADG2) and ADG-overall.
2Calves diagnosed as sBRD: CRS + TUS < 5 and lung consolidation ≥ 1 cm2.
3Calves diagnosed with BRD (CRS + TUS ≥ 5) without lung consolidation.
4Calves diagnosed with BRD (CRS + TUS ≥ 5) with lung consolidation ≥ 1 cm2.
a,bWithin columns, Lsmeans differ between treatments by P ≤ 0.05.